StockVS

Kenvue Inc. (KVUE) 주식 분석

필수소비재

Kenvue Inc.

$17.49

$-0.04 (-0.23%)

최종 업데이트: 2026년 5월 26일

가격 추이

최신 뉴스

제3자 소스에서 제공된 뉴스입니다. 투자 조언이 아닙니다.

분석

회사 개요

Kenvue Inc. operates as a prominent consumer health entity serving markets across the United States, North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. The corporation generates revenue through three distinct business segments: Self Care, Skin Health and Beauty, and Essential Health, providing a diverse portfolio of over-the-counter products. This enterprise is categorized within the Consumer Defensive sector and specifically functions in the Household & Personal Products industry, which typically exhibits lower sensitivity to economic downturns compared to cyclical sectors. The company demonstrates substantial scale with a market capitalization of $33.41B and an annual revenue of $15.12B, supported by a workforce of 21,780 employees. These valuation and revenue figures indicate that Kenvue maintains a significant position within the global consumer health landscape, reflecting a mature business model with established distribution channels and brand recognition that supports its large market cap.

재무 건전성

Kenvue Inc. reported a trailing twelve-month revenue of $15.12B and a net income of $1.47B, while generating an EBITDA of $3.24B during the same period. The substantial gap between the $15.12B revenue and the $1.47B net income reveals a cost structure where operating expenses, taxes, and interest consume approximately 90.3% of top-line sales, leaving a profit margin of 9.7%. The company generated free cash flow of $1.81B, which signifies a strong ability to fund capital expenditures, service debt, and return capital to shareholders without relying on external financing. Regarding liquidity and leverage, the company holds $1.06B in cash against total debt of $8.67B, resulting in a debt-to-equity ratio of 80.58 that suggests a leveraged balance sheet typical for capital-intensive consumer goods companies. However, the current ratio stands at 0.96, indicating that the company's current assets are slightly lower than its current liabilities, which requires careful management of short-term obligations. Management effectiveness is further highlighted by a return on equity of 14.4% and a return on assets of 6.6%, demonstrating efficient utilization of shareholder capital and the asset base to generate profits. The gross margin of 58.4% reflects strong pricing power or cost advantages in sourcing ingredients and manufacturing, while the operating margin of 17.8% shows effective control over overhead costs.

밸류에이션 평가

The valuation metrics for Kenvue show a trailing P/E ratio of 22.93 and a forward P/E of 14.38, implying that the market expects earnings to grow significantly in the coming year to justify the lower forward multiple. The price-to-book ratio is 3.10, indicating that the market values the company at more than three times its book value, which suggests investors are willing to pay a premium for its brand equity and intangible assets. Alternative valuation measures include a price-to-sales ratio of 2.21 and an EV/EBITDA of 12.65, which provide context for the company's value relative to its sales volume and earnings power before interest, taxes, depreciation, and amortization. The stock has traded between a 52-week low of $14.02 and a 52-week high of $25.17, with the current price sitting in a range that reflects market sentiment towards its defensive characteristics and dividend profile. With a beta of 0.57, Kenvue exhibits lower volatility than the broader market, making it an attractive option for portfolios seeking stability during periods of heightened equity market fluctuations.

Growth & Income

Kenvue Inc. achieved a year-over-year revenue growth of 3.2% and an earnings growth of 11.2%, indicating that profitability is expanding at a rate more than three times faster than top-line sales. This divergence suggests successful cost management or pricing power that allows the company to translate revenue gains into disproportionately higher net income. As a consistent dividend payer, the company offers a dividend yield of 4.8% with a payout ratio of 108.5%, which implies that the company is distributing more in dividends than it currently reports in net income, often supported by cash flow rather than accounting earnings. The high payout ratio requires close monitoring as it may not be sustainable if earnings growth slows significantly in the future. Overall, Kenvue presents a growth and income profile characterized by steady revenue expansion, accelerating earnings per share, and a substantial dividend yield that appeals to income-focused investors.

동종업체 비교

Kenvue Inc. (KVUE) 은(는) 가정용 및 개인 용품 산업에서 운영됩니다. 시가총액 기준으로 가장 가까운 동종업체와의 비교는 다음과 같습니다:

기업명 티커 시가총액 PER
Kenvue Inc. KVUE $33.58B 20.8
The Procter & Gamble Company PG $336.34B 21.1
Unilever PLC UL $123.97B 19.0
Colgate-Palmolive Company CL $71.90B 34.8

가정용 및 개인 용품 산업 평균 PER은 29.9배입니다. Kenvue Inc.의 PER은 20.8입니다.

이 분석은 AI가 생성한 것으로 정보 제공 목적으로만 사용되며 투자 조언이 아닙니다. 데이터가 지연되거나 부정확할 수 있습니다. 투자 결정을 내리기 전에 항상 직접 조사하고 자격을 갖춘 재무 상담사와 상담하세요.

Kenvue Inc. 소개

Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

회사 설명은 영어로 표시됩니다.

웹사이트 방문 →

주요 지표

시가총액
$33.58B
PER
20.82
52주 최고가
$23.94
52주 최저가
$14.02
평균 거래량
20.88M
베타
0.52
배당수익률
4.75%

데이터는 yfinance를 통해 Yahoo Finance에서 제공됩니다. 매일 업데이트.

기업 정보

거래소
NYSE
국가
United States
직원 수
21,780